ABVC BioPharma Announces Corporate Restructuring and Commercialization Strategy

ABVC BioPharma, Inc. provided an update on its subsidiary structure, regulatory progress, and ongoing commercialization planning. The clinical-stage biopharmaceutical company is advancing the structured commercialization of its intellectual property portfolio through licensing and operating platforms established across its subsidiary ecosystem. Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the company is continuing to transition select mature intellectual property assets toward structured commercial pathways through dedicated subsidiary platforms. This framework is intended to support ongoing partnership discussions, potential manufacturing collaborations, and formulation-based licensing initiatives under strategic evaluation.

The company's approach is designed to enhance operational transparency, governance alignment, and coordination across licensing, manufacturing, and co-development activities within the ABVC group. As part of ABVC's broader commercialization strategy, the company established BioKey (Cayman), Inc. to support global manufacturing alignment and regional market entry initiatives related to its functional ingredient and nutraceutical portfolio. BioKey Cayman is structured to facilitate formulation-based licensing initiatives, contract manufacturing collaborations, and co-branding and distribution partnerships.

Management believes this structure may support future commercial arrangements for the specified products as programs advance through development and scale-up planning. The company is also making progress toward making BioKey Cayman a separate, public reporting and listed entity and will provide updates when permissible and appropriate. BioKey Cayman is a Cayman Islands-incorporated life sciences and nutraceutical platform within the ABVC BioPharma group, focused on the development, formulation, and commercialization of botanical-based functional ingredients, dietary supplements, and contract research, development, and manufacturing services.

Through its operating subsidiaries and affiliates, BioKey supports product innovation, regulatory-aligned manufacturing, and business-to-business commercialization across select international markets. The company is positioning itself to operate as an independent public entity, with an emphasis on scalable product development, quality-driven manufacturing, and long-term value creation in the global nutraceutical and functional health sectors. ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device under development.

For its drug products, the company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For its medical device Vitargus, the company intends to conduct pivotal clinical trials through global partnerships. More detailed information about the company and risk factors is set forth in the company's filings with the Securities and Exchange Commission, which investors can read free of charge on the SEC's website at https://www.sec.gov.